
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 ~2x weekly·179 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
Multidisciplinary Coordination in TK2d Diagnosis and Management
Jun 24, 2026
Unknown duration
Advancing MOGAD Care
Jun 24, 2026
Unknown duration
Navigating Stem Cell Therapy Conversations in MS
Jun 8, 2026
4m 45s
Cognitive Screening in MS: Practical Strategies and Modern Approaches
May 28, 2026
3m 30s
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
May 14, 2026
14m 45s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/24/26 | ![]() Multidisciplinary Coordination in TK2d Diagnosis and Management | Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Zarazuela Zolkipli-Cunningham, MBChB, MRCP Guest: Oscar H. (Hank) Mayer, MD Thymidine kinase 2 deficiency (TK2d) is a rare mitochondrial myopathy that can involve multiple organ systems, requiring care from different specialties. Given that need for multidisciplinary coordination, Dr. Charles Turck speaks with Drs. Hank Mayer and Zuela Zolkipli-Cunningham to learn how we can improve communication and collaboration across the care team throughout the diagnostic and management journey. Coming to us from the Children's Hospital of Philadelphia, Dr. Mayer is the Director of the Pulmonary Function Laboratory, and Dr. Zolkipli-Cunningham is the Director of Clinical Research in the Mitochondrial Medicine Frontier Program. | — | ||||||
| 6/24/26 | ![]() Advancing MOGAD Care | No Label: Michael Levy, MD, PhD No Label: Peter V. Sguigna, MD What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX. | — | ||||||
| 6/8/26 | ![]() Navigating Stem Cell Therapy Conversations in MS✨ | stem cell therapymultiple sclerosis+3 | Jaime Imitola, MDJaime Imitola | UConn Health | multiple sclerosis | stem cell therapymultiple sclerosis+3 | — | 4m 45s | |
| 5/28/26 | ![]() Cognitive Screening in MS: Practical Strategies and Modern Approaches✨ | cognitive screeningmultiple sclerosis+3 | Elizabeth S. Gromisch, PhDElizabeth S. Gromisch | Joyce D. and Andrew J. Mandell Center for Comprehensive Multiple Sclerosis Care and Neuroscience ResearchMount Sinai Rehabilitation Hospital+1 | — | cognitive changesscreening tools+3 | — | 3m 30s | |
| 5/14/26 | ![]() Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role✨ | respiratory symptomspulmonologist role+3 | Bethany Lussier | UT Southwestern Medical CenterDivision of Pulmonary and Critical Care Medicine | — | TK2drespiratory manifestations+3 | — | 14m 45s | |
| 5/14/26 | ![]() Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols✨ | thymidine kinase 2 deficiencyneuromuscular disorders+3 | Kaitlin Batley | Children’s HealthUT Southwestern Medical Center | — | TK2dfatigue+5 | — | 13m 30s | |
| 5/1/26 | ![]() Understanding Variability in Myasthenia Gravis✨ | Myasthenia Gravistreatment variability+3 | Henry Kaminski, MDHenry Kaminski | The George Washington University School of Medicine and Health Sciences | — | Myasthenia Gravistreatment variability+3 | — | 3m 45s | |
| 4/30/26 | ![]() Examining the Global Genetic Prevalence of TK2d✨ | genetic prevalencethymidine kinase 2 deficiency+3 | Austin Larson, MD | University of Colorado Anschutz | — | TK2dthymidine kinase 2 deficiency+3 | — | 14m 01s | |
| 3/30/26 | ![]() Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis✨ | multiple sclerosisMcDonald criteria+5 | Aaron Miller, MDAaron Miller | Corinne Goldsmith Dickinson Center for Multiple SclerosisIcahn School of Medicine at Mount Sinai | — | multiple sclerosisMcDonald criteria+5 | — | 3m 00s | |
| 2/19/26 | ![]() Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers✨ | multiple sclerosisaging signatures+3 | Adil Harroud, MDDylan Hamitouche+1 | Montreal Neurological InstituteMcGill University | — | multiple sclerosisaging signatures+3 | — | 10m 45s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 2/19/26 | ![]() Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care✨ | multiplex proteomic biomarkersmultiple sclerosis+4 | Raphael Schneider, MD, PhD, FRCPC, CIPRaphael Schneider | BARLO MS CentreSt. Michael’s Hospital+1 | — | multiplex proteomic biomarkersmultiple sclerosis+4 | — | 5m 15s | |
| 2/19/26 | ![]() Understanding Accelerated Biological Aging in Pediatric MS✨ | pediatric multiple sclerosisbiological aging+3 | Jennifer Yang, MDJennifer Yang | UC San Diego School of MedicineRady Children's Hospital | — | multiple sclerosispediatric neurology+3 | — | 5m 15s | |
| 1/16/26 | ![]() Parkinson’s Research in Focus: Translating Science Into Clinical Progress | Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Michael Salvatore, PhD Guest: Vicki Nejtek-Salvatore, PhD Translational research is reshaping the way we understand, detect, and manage Parkinson’s disease. To learn more about how current research efforts are uncovering early biomarkers and redefining intervention strategies, Dr. Jerome Lisk sits down with Dr. Michael Salvatore and Dr. Vicki Nejtek-Salvatore, professors at University of North Texas Health Science Center in Fort Worth and co-founders of the Parkinson Discovery Institute in Fort Worth, Texas. | — | ||||||
| 12/10/25 | ![]() Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care | Guest: Ashvini Keshavan, MRCP, PhD Very few patients in UK memory services receive an Alzheimer’s diagnosis supported by molecular testing, limiting timely access to emerging therapies. The ADAPT trial—which was funded by the Blood Biomarker Challenge, a multi-million-pound program supported by the Alzheimer's Society, Alzheimer's Research UK, and players of People's Postcode Lottery—aims to close this gap by evaluating the real-world integration of blood-based biomarkers into standard NHS memory care pathways. Join Dr. Ashvini Keshavan as she discusses how this approach may impact diagnostic accuracy, treatment access, and healthcare resource use across the UK. Dr. Keshavan is a Senior Clinical Research Fellow and Honorary Consultant Neurologist specializing in Alzheimer’s disease biomarkers at the University College London, and this topic was presented as a poster at the 2025 CTAD conference. | — | ||||||
| 9/29/25 | ![]() Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant | Guest: Sergio Baranzini, PhD In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). | — | ||||||
| 9/29/25 | ![]() Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS | Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress. | — | ||||||
| 9/29/25 | ![]() Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics | Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress. | — | ||||||
| 9/17/25 | ![]() Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers | Host: Ryan Quigley A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). | — | ||||||
| 8/26/25 | ![]() The Future of MS Management: Novel Agents and Clinical Approaches | Guest: Marisa McGinley, DO The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, including the BEAT-MS trial, with Dr. Marisa McGinley, a neurologist at the Cleveland Clinic. | — | ||||||
| 8/20/25 | ![]() Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis | Early symptoms of multiple sclerosis (MS) often present as clear, localized neurological changes lasting several days. However, many nonspecific complaints and common MRI findings can mimic MS, leading to misdiagnosis and unnecessary treatment. Dr. Jonathan Howard, an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital, reviews hallmark symptom patterns, explains how to differentiate benign MRI changes from true disease, and underscores the importance of thorough history-taking, neurological exams, and targeted testing to ensure accurate diagnosis and optimal patient care. | — | ||||||
| 8/20/25 | ![]() Modern MS Care: Navigating Treatment Options for Better Patient Outcomes | Since 2010, the landscape of multiple sclerosis care has transformed to encompass a variety of medications, each having unique benefits, risks, and side effect profiles. Dr. Jonathan Howard discusses how to match treatment strength to disease severity and balance patient risk tolerance with evolving therapeutic options, from long-standing injectables to infusions and oral therapies. Dr. Howard is an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital in New York. | — | ||||||
| 8/19/25 | ![]() Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy | Guest: David Gate, PhD Patients with Alzheimer's disease—especially APOE4 carriers—show distinct epigenetic immune alterations that may influence disease progression, treatment response, and side effect risk. In this episode, Dr. David Gate, an Assistant Professor of Behavioral Neurology at Northwestern University, dives into his research on this subject and explains how chromatin accessibility in proinflammatory genes and T-cell receptor changes link to neurological pathology. | — | ||||||
| 8/14/25 | ![]() Understanding MS: Managing Hidden and Overlooked Symptoms | Guest: Marisa McGinley, DO Multiple sclerosis (MS) presents with far more than just mobility issues—fatigue, spasticity, bladder and bowel dysfunction, cognitive changes, and mood disorders are frequently underrecognized but deeply impactful. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, explains how to identify subtle clinical changes, utilize patient-reported outcomes, and engage in proactive symptom discussions that support timely interventions. | — | ||||||
| 8/14/25 | ![]() Advancing MS Care: Evolving Treatments and High-Efficacy Approaches | Guest: Marisa McGinley, DO Multiple sclerosis (MS) treatment has transformed dramatically, with a wide range of high-efficacy options currently available. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, explores how advancements in drug availability, administration methods, and efficacy are reshaping care, with a focus on sequencing strategies and the growing movement toward early, aggressive treatment. Learn how to integrate patient preferences, comorbidities, and shared decision-making into personalized therapy plans. | — | ||||||
| 8/13/25 | ![]() Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care | Guest: Marisa McGinley, DO Multiple sclerosis (MS) presents a diverse range of symptoms that require coordinated, expert care. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, provides practical strategies for neurologists to serve as the central point of contact for patients with MS, initiate targeted treatments, and engage a variety of specialty teams in collaborative management. | — | ||||||
Showing 25 of 184
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
